288 related articles for article (PubMed ID: 14512193)
1. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
Hoang T; Kim K; Jaslowski A; Koch P; Beatty P; McGovern J; Quisumbing M; Shapiro G; Witte R; Schiller JH
Lung Cancer; 2003 Oct; 42(1):97-102. PubMed ID: 14512193
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
Masters GA; Declerck L; Blanke C; Sandler A; DeVore R; Miller K; Johnson D;
J Clin Oncol; 2003 Apr; 21(8):1550-5. PubMed ID: 12697880
[TBL] [Abstract][Full Text] [Related]
3. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Dimopoulos AM; Kosmidis P; Papakostas P; Pavlidis N; Bacoyiannis C; Kiamouris C; Klouvas G; Gogas H; Fountzilas G; Samantas E;
Lung Cancer; 2003 Jul; 41(1):107-11. PubMed ID: 12826319
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Moore AM; Einhorn LH; Estes D; Govindan R; Axelson J; Vinson J; Breen TE; Yu M; Hanna NH
Lung Cancer; 2006 Apr; 52(1):93-7. PubMed ID: 16488055
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Rocha-Lima CM; Herndon JE; Lee ME; Atkins JN; Mauer A; Vokes E; Green MR;
Ann Oncol; 2007 Feb; 18(2):331-7. PubMed ID: 17065590
[TBL] [Abstract][Full Text] [Related]
8. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
9. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
12. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
De Marinis F; Migliorino MR; Paoluzzi L; Portalone L; Ariganello O; Cortesi E; Gamucci T; Gasperoni S; Cipri A; Martelli O; Nelli F;
Lung Cancer; 2003 Mar; 39(3):331-8. PubMed ID: 12609572
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Strojan P
J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
[TBL] [Abstract][Full Text] [Related]
16. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
Hesketh PJ; Chansky K; Israel V; Grapski RT; Mekhail TM; Spiridonidis CH; Mills GM; Kelly K; Crowley JJ; Gandara DR
J Thorac Oncol; 2007 May; 2(5):440-4. PubMed ID: 17473660
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer.
Cok G; Göksel T; Soyer S; Aysan T
Tuberk Toraks; 2008; 56(1):74-80. PubMed ID: 18330758
[TBL] [Abstract][Full Text] [Related]
20. Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.
Karampeazis A; Vamvakas L; Kentepozidis N; Polyzos A; Chandrinos V; Rigas G; Christofyllakis C; Kotsakis A; Hatzidaki D; Pallis AG; Georgoulias V
Clin Lung Cancer; 2016 Nov; 17(6):543-549. PubMed ID: 27397849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
